BIONET (1784) Stock Overview
Provides cell therapy services in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Risk Analysis
No risks detected for 1784 from our risk checks.
1784 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BIONET Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$69.80 |
| 52 Week High | NT$162.01 |
| 52 Week Low | NT$62.40 |
| Beta | 0.50 |
| 1 Month Change | -3.59% |
| 3 Month Change | -13.18% |
| 1 Year Change | -7.94% |
| 3 Year Change | 88.29% |
| 5 Year Change | 107.64% |
| Change since IPO | 426.46% |
Recent News & Updates
Shareholder Returns
| 1784 | TW Healthcare | TW Market | |
|---|---|---|---|
| 7D | -1.4% | 0.9% | 1.2% |
| 1Y | -7.9% | -15.1% | -0.7% |
Return vs Industry: 1784 exceeded the TW Healthcare industry which returned -15.1% over the past year.
Return vs Market: 1784 underperformed the TW Market which returned -0.7% over the past year.
Price Volatility
| 1784 volatility | |
|---|---|
| 1784 Average Weekly Movement | 7.1% |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in TW Market | 10.1% |
| 10% least volatile stocks in TW Market | 4.9% |
Stable Share Price: 1784 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1784's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Qing Yuan Kang | www.bionetcorp.com |
BIONET Corp. provides cell therapy services in Taiwan and internationally. The company offers stem cell banking services, including stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and peripheral blood stem cells and immune cells; and genetic testing services. It also provides stem anti-aging and ANIKINE series products; and Exosome, a novel cell-free therapy.
BIONET Corp. Fundamentals Summary
| 1784 fundamental statistics | |
|---|---|
| Market cap | NT$3.54b |
| Earnings (TTM) | NT$76.54m |
| Revenue (TTM) | NT$1.22b |
Is 1784 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1784 income statement (TTM) | |
|---|---|
| Revenue | NT$1.22b |
| Cost of Revenue | NT$535.21m |
| Gross Profit | NT$681.18m |
| Other Expenses | NT$604.64m |
| Earnings | NT$76.54m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.51 |
| Gross Margin | 56.00% |
| Net Profit Margin | 6.29% |
| Debt/Equity Ratio | 2.8% |
How did 1784 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/05 09:14 |
| End of Day Share Price | 2025/06/05 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BIONET Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiaowei Huang | Masterlink Securities Corp. |